Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 25;22(1):71.
doi: 10.1186/s12882-021-02267-4.

Low plasma magnesium concentration and future abdominal aortic calcifications in moderate chronic kidney disease

Affiliations

Low plasma magnesium concentration and future abdominal aortic calcifications in moderate chronic kidney disease

Anique D Ter Braake et al. BMC Nephrol. .

Abstract

Background: Higher plasma magnesium concentrations are associated with reduced cardiovascular disease risk in chronic kidney disease (CKD) patients. The importance of plasma magnesium concentration for vascular calcification in earlier stages of CKD remains underexplored. This study investigated whether plasma magnesium is a determinant for the presence and severity of vascular calcification in moderate CKD.

Methods: Retrospective analysis was performed using abdominal aortic calcification (AAC) scores in 280 patients with stage 3 and 4 CKD enrolled in the MASTERPLAN trial. Lateral abdominal X-ray was used to evaluate AAC. Plasma magnesium concentration were measured over time. A zero-inflated Poisson model determined the association between plasma magnesium concentration and AAC.

Results: 79 out of 280 patients did not have AAC, and in patients with AAC the median calcification score was 3.5 (interquartile range: 0.0-8.6). The mean plasma magnesium concentration was 0.76 ± 0.10 mmol/L at baseline. A 0.1 mmol/L higher plasma magnesium concentration was associated with lower AAC of 0.07 point (95% CI -0.28 - 0.14). A 0.1 mmol/L higher plasma magnesium lowered the odds of detecting any AAC by 30% (OR = 0.63; 95% CI 0.29-1.37). After 1 year and 4 years (at time of X-ray) of follow-up this association was attenuated (OR = 0.93; 95% CI 0.61-1.43 and 0.93; 95% CI 0.60-1.45, respectively). None of these associations reached statistical significance.

Conclusions: Plasma magnesium concentration at baseline is not associated with the risk for future AAC. Interventions increasing magnesium to avoid vascular calcification may have greatest potential in early CKD stages prior to onset of vascular calcification.

Keywords: Abdominal aortic calcification score; Chronic kidney disease; Magnesium; Vascular calcification.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Plasma Mg2+ concentrations in non-dialysis CKD patients. Distribution of Mg2+ concentrations (A). Plasma Mg2+ concentrations for CKD patients with (indicated in white) and without (indicated in black) abdominal aortic calcifications (B). Dotted vertical lines indicate the reference values for Mg2+ concentration (0.7–1.1 mmol/L)
Fig. 2
Fig. 2
Dose-response relation between Mg2+ and abdominal aortic calcification score. The abdominal aortic calcification (AAC)-score for each patient are presented individually and plotted against their plasma Mg2+ concentration at baseline. Dose-response relation between AAC and plasma Mg2+ concentration was investigated by creating a scatter plot and fitting a LOESS smoothed regression line. No transformations were considered due to linearity of the association. Dotted vertical lines indicate the reference values for Mg2+ concentration (0.7–1.1 mmol/L)

References

    1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update. Circulation. 2016;133:447–454. doi: 10.1161/CIR.0000000000000366. - DOI - PubMed
    1. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998;11:239–245. - PubMed
    1. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483. doi: 10.1056/NEJM200005183422003. - DOI - PubMed
    1. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008;19:1092–1105. doi: 10.1681/ASN.2007070760. - DOI - PMC - PubMed
    1. Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD) Cochrane Database Syst Rev. 2018;8(8):CD006023. - PMC - PubMed

Publication types